Track ProMIS Neurosciences Inc. Common Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ProMIS Neurosciences Inc. Common Shares PMN Open ProMIS Neurosciences Inc. Common Shares in new tab

10.44 USD
EPS
-18.60
P/B
1.53
ROE
-115.73
Beta
-0.09
Target Price
34.34 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 17, 2026
EPS-18.60
Book Value6.77
Price to Book1.53
% Insiders26.286%
Estimates
Forward P/E-17.03
Forward EPS-0.61
Target Mean Price34.34

DCF Valuation

Tweak assumptions to recompute fair value for ProMIS Neurosciences Inc. Common Shares (PMN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

ProMIS Neurosciences Inc. Common Shares Logo ProMIS Neurosciences Inc. Common Shares Analysis (PMN)

Canada Health Care Official Website Stock

Is ProMIS Neurosciences Inc. Common Shares a good investment? ProMIS Neurosciences Inc. Common Shares (PMN) is currently trading at 10.44 USD. Market analysts have a consensus price target of 34.34 USD. This suggests a potential upside from current levels.

Earnings Schedule: ProMIS Neurosciences Inc. Common Shares is expected to release its next earnings report on Aug. 17, 2026. The market consensus estimate for Forward EPS is -0.61.

Investor FAQ

Does ProMIS Neurosciences Inc. Common Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is ProMIS Neurosciences Inc. Common Shares?

ProMIS Neurosciences Inc. Common Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 17, 2026. The company currently has a trailing EPS of -18.60.

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Exchange Ticker
NMS (United States) PMN

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
June 28, 2022 0.020000
June 28, 2022 0.016667
Nov. 28, 2025 0.040000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion